CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-15 | Ogden Christopher Chief Financial Officer | Sale | −1,624 | $3.05 | $5K | 295,324 |
| 2026-03-17 | Chu Yu-Waye Chief Medical Officer | Sale | −21,279 | $6.42 | $137K | 189,446 |
| 2026-03-17 | McCarthy Sean A. CEO | Sale 10b5-1 | −118,969 | $6.42 | $764K | 1,078,922 |
| 2026-03-17 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −31,492 | $6.42 | $202K | 300,760 |
| 2026-03-17 | Ogden Christopher Chief Financial Officer | Sale | −19,323 | $6.42 | $124K | 296,948 |
| 2025-11-06 | McCarthy Sean A. CEO | Sale 10b5-1 | −101,793 | $4.54 | $462K | 1,089,684 |
| 2025-11-06 | McCarthy Sean A. CEO | Sale 10b5-1 | −101,793 | $4.54 | $462K | 987,891 |
| 2025-06-16 | Ogden Christopher Chief Financial Officer | Sale | −10,614 | $2.69 | $29K | 226,271 |
| 2025-06-16 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −13,884 | $2.69 | $37K | 272,252 |
| 2025-06-16 | McCarthy Sean A. CEO | Sale | −55,511 | $2.69 | $149K | 1,089,684 |
| 2025-06-13 | Ogden Christopher Chief Financial Officer | Sale | −1,641 | $2.95 | $5K | 199,385 |
| 2025-03-18 | McCarthy Sean A. CEO | Sale | −37,656 | $0.60 | $23K | 995,195 |
| 2025-03-18 | Ogden Christopher Chief Financial Officer | Sale | −8,551 | $0.60 | $5K | 201,026 |
| 2025-03-18 | Chu Yu-Waye Chief Medical Officer | Sale | −4,025 | $0.60 | $2K | 135,725 |
| 2025-03-18 | ROWLAND LLOYD A General Counsel | Sale | −10,203 | $0.60 | $6K | 120,594 |
| 2025-03-18 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −19,512 | $0.60 | $12K | 248,636 |
| 2024-08-20 | Landau Jeffrey B Chief Business Officer | Sale | −4,181 | $1.23 | $5K | 119,056 |
| 2024-08-20 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −4,181 | $1.23 | $5K | 175,648 |
| 2024-08-20 | ROWLAND LLOYD A General Counsel | Sale | −4,181 | $1.23 | $5K | 130,797 |
| 2024-08-20 | Ogden Christopher Chief Financial Officer | Sale | −1,984 | $1.23 | $2K | 108,077 |
Page 1 of 10 · 182 trades